Brief: Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Bioatla

23/09/2024 14:12

Sept 23 (Reuters) - Bioatla Inc  BCAB.O :
    * BIOATLA AND CONTEXT THERAPEUTICS ANNOUNCE EXCLUSIVE
WORLDWIDE
LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE BA3362, A
NECTIN-4 X CD3 T CELL ENGAGING ANTIBODY
    * CONTEXT THERAPEUTICS INC - BIOATLA TO RECEIVE $15 MILLION
UPFRONT, UP TO $118.5 MILLION IN MILESTONES
    * CONTEXT THERAPEUTICS INC - ANTICIPATES IND FILING FOR
BA3362 IN
MID-2026

Source text for Eikon:  ID:nGNX6nwnt3 
Further company coverage:  BCAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))